受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder | ||||
化学式 | C47H44ClFN6O6S |
||||||
分子量 | 875.41 | CAS No. | 1799631-75-6 | ||||
Solubility (25°C)* | 体外 | DMSO | 100 mg/mL (114.23 mM) | ||||
Water | Insoluble | ||||||
体内 (毎回新しく調製した物を用意してください) |
|
||||||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | MIK665 (S64315) is an inhibitor of induced myeloid leukemia cell differentiation protein Mcl-1 with Ki value of 1.2 nM and has potential pro-apoptotic and antineoplastic activities. |
---|---|
in vitro | S64315 (MIK665) is an inhibitor of induced myeloid leukemia cell differentiation protein Mcl-1. [2] |
in vivo | S64315 (MIK665) is an inhibitor of induced myeloid leukemia cell differentiation protein Mcl-1. [2] |
細胞アッセイ | 細胞株 | H929 cells |
---|---|---|
濃度 | 26 pM (Ki) | |
反応時間 | 6 h | |
実験の流れ | H929 cells were treated for 6 h with increasing concentration of S64315. |
|
動物実験 | 動物モデル | Female CB-17 SCID mice |
投薬量 | 12.5 mg/kg | |
投与方法 | i.v. |
|
Structural optimization of siRNA conjugates for albumin binding achieves effective MCL1-directed cancer therapy [ Nat Commun, 2024, 15(1):1581] | PubMed: 38383524 |
Targeting MCL-1 triggers DNA damage and an anti-proliferative response independent from apoptosis induction [ Cell Rep, 2023, 42(10):113176] | PubMed: 37773750 |
Simultaneous Inhibition of Mcl-1 and Bcl-2 Induces Synergistic Cell Death in Hepatocellular Carcinoma [ Biomedicines, 2023, 11(6)1666] | PubMed: 37371761 |
Structural Optimization of siRNA Conjugates for Albumin Binding Achieves Effective MCL1-Targeted Cancer Therapy [ bioRxiv, 2023, 2023.02.14.528574] | PubMed: 36824780 |
MCL1 Inhibitors S63845/MIK665 Plus Navitoclax Synergistically Kill Difficult-To-Treat Melanoma Cells [ Cell Death Dis, 2020, 8;11(6):443] | PubMed: 32513939 |
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. [ Blood Adv, 2020, 4(5):819-829] | PubMed: 32126142 |
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma [ Cancers (Basel), 2020, 12(8):E2182] | PubMed: 32764384 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。